BPC-157

What it is

BPC-157 is a synthetic peptide made of 15 amino acids. The sequence was originally identified in human stomach juice — researchers in Croatia noticed that something in gastric fluid was protecting the stomach lining from ulcers, and they isolated the active fragment.

It became popular outside the lab because animal studies kept reporting unusually fast healing in tendons, ligaments, gut and skin. There is no human clinical trial data of any size, so everything reported in people is anecdote.

History

First described in scientific literature around 1991 by Predrag Sikiric and colleagues at the University of Zagreb. Roughly three decades old. Has been studied in dozens of rat and rabbit models but has never completed a Phase III human trial.

How it works

Best evidence points to upregulation of growth-hormone receptors at injury sites and increased blood vessel formation (angiogenesis) via the VEGFR2 pathway. In plain terms: it seems to make damaged tissue more receptive to repair signals it would respond to anyway.

Dosage

• Common research range: 250 mcg to 500 mcg, once or twice daily.
• Typical course: 4–6 weeks on, then break. People treating a specific injury often pin closer to the site.
• There is no established "right" human dose — these ranges come from extrapolation off animal studies and community reports.

How it is taken

• Subcutaneous injection into the belly fat with a 29–31G insulin syringe is the most common route.
• Some users inject intramuscularly close to the injured area (e.g. into the calf for an Achilles issue). The evidence that site-specific injection beats systemic injection in humans is weak but not zero.
• Oral BPC-157 is sold but absorption from the gut is poor. It may still be useful for gut-specific issues because it works locally on the GI lining.

How to reconstitute

• A 5 mg vial reconstituted with 2 ml of bacteriostatic water gives 2.5 mg/ml. At 250 mcg per dose, that is 10 units on a 1 ml insulin syringe.
• Inject the BAC water slowly down the inside of the vial wall — do not blast it onto the powder. Swirl gently to dissolve. Do not shake.

How it should arrive

Sealed glass vial, intact crimped aluminium cap, with a fine white fluffy powder or a thin white "puck" at the bottom. The vial should be under slight vacuum — when you pierce it with a needle of BAC water, water should pull in slightly.

How it should look once reconstituted

Clear, colourless and free of particles after gentle swirling. If it looks cloudy, has flecks, or there is residue stuck to the wall after a few minutes, something is wrong.

What to expect, and when

• Gut issues (gastritis, IBS-type discomfort): some people report improvement inside a week.
• Soft-tissue injuries (tendinopathy, sprains, post-surgical): typical anecdotal timeline is 2–6 weeks of daily injections.
• If you have not noticed anything after 6 weeks of consistent dosing, the realistic conclusion is that BPC-157 is not doing anything useful for your situation.

Side effects

• Most users report none.
• Reported: temporary fatigue, mild dizziness, headache, occasional changes in heart rate or blood pressure.
• Injection-site irritation is common with intramuscular injections.

Risks

• Long-term human safety data does not exist. Angiogenesis (new blood vessel formation) is part of the proposed mechanism, and angiogenesis is also a process that supports tumour growth — there is no evidence BPC-157 causes cancer, but no one has run the long-term studies that would rule it out.
• WADA bans BPC-157 for athletes under the S0 "non-approved substances" category.

Potential gains

• Faster healing of tendons, ligaments, muscle tears in animal models.
• Reduced inflammation in the gut lining (animal data on ulcerative colitis and NSAID-induced gastritis).
• Some users report reduced joint pain.

Other useful information

Often stacked with TB-500 for compound healing protocols — the reasoning is that BPC-157 promotes local repair while TB-500 supports systemic cell migration. There is no high-quality human evidence that the stack outperforms either alone.